Patents by Inventor Claus-Jens W. Doersen
Claus-Jens W. Doersen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 5292656Abstract: The present invention relates to a novel cell line isolated from a rat osteosarcoma wherein the cell line has the following characteristics: a) normal p53 gene as compared to a non-tumorigenic Sprague-Dawley rat cell control; b) normal RB-1 gene as compared to a non-tumorigenic Sprague-Dawley rat cell control; c) a normal c-myc gene as compared to a non-tumorigenic Sprague-Dawley rat cell control; d) a normal c-fos gene as compared to a non-tumorigenic Sprague-Dawley rat cell control; e) a deregulated immediate early gene response; f) a canalicular network MATRIGEL.TM.Type: GrantFiled: June 24, 1992Date of Patent: March 8, 1994Assignee: The Procter & Gamble CompanyInventors: Claus-Jens W. Doersen, Robert J. Isfort
-
Patent number: 5288628Abstract: The present invention relates to a novel cell line isolated from a rat osteosarcoma wherein the cell line has the following characteristics: a) a mutated p53 system, b) a normal RB-1 gene as compared to a non-tumorigenic Sprague-Dawley rat cell control, c) a normal c-myc gene as compared to a non-tumorigenic Sprague-Dawley rat cell control, d) a normal c-fos gene as compared to a non-tumorigenic Sprague-Dawley rat cell control, e) a deregulated immediate early gene response, f) a canalicular network MATRIGEL.TM.Type: GrantFiled: June 24, 1992Date of Patent: February 22, 1994Assignee: The Procter & Gamble CompanyInventors: Claus-Jens W. Doersen, Robert J. Isfort
-
Patent number: 5286644Abstract: The present invention relates to a novel cell line isolated from a rat osteosarcoma having the following characteristics: a) a normal p53 gene as compared to a non-tumorigenic Sprague-Dawley rat cell control; b) a normal RB-1 gene as compared to a non-tumorigenic Sprague-Dawley rat cell control; c) a normal c-myc gene as compared to a non-tumorigenic Sprague-Dawley rat cell control; d) a normal c-fos gene as compared to a non-tumorigenic Sprague-Dawley rat cell control; e) a normal immediate early gene response following mitogenic stimulation; f) a canalicular Matrigel growth pattern; g) non-tumorigenic in congenitally athymic mice; h) high levels of alkaline phosphatase activity; i) a lack of autocrine growth factor production; and j) an ability to be serially propagated greater than sixty population doublings.Type: GrantFiled: June 24, 1992Date of Patent: February 15, 1994Assignee: The Procter & Gamble CompanyInventors: Claus-Jens W. Doersen, Robert J. Isfort
-
Patent number: 5286643Abstract: The present invention relates to a novel cell line isolated from a rat osteosarcoma wherein the cell line has the following characteristics: a) a normal p53 gene; b) a normal RB-1 gene; c) a normal c-myc gene; d) a normal c-fos gene; e) a deregulated immediate early gene response; f) a canalicular network MATRIGEL.TM. growth pattern; g) poorly tumorigenic in congenitally athymic mice; h) no alkaline phosphatase activity; i) an ability to produce one or more of the following growth factors: 1) a non-heparin binding growth factor, 2) a first heparin binding growth factor, 3) a second heparin binding growth factor, and 4) a third heparin binding growth factor; and j) an ability to be serially propagated greater than sixty population doublings.The present invention also relates to growth factors having the characteristics of growth factors isolated from the rat osteosarcoma cell line.Type: GrantFiled: June 24, 1992Date of Patent: February 15, 1994Assignee: The Procter & Gamble CompanyInventors: Claus-Jens W. Doersen, Robert J. Isfort
-
Patent number: 5286642Abstract: The present invention relates to a novel cell line isolated from a rat osteosarcoma cell line has the following characteristics: a) a non-expressed p53 protein; b) a normal RB-1 gene; c) a 1O.times. amplified c-myc gene; d) a normal c-fos gene; e) a deregulated immediate early gene response; f) a canalicular network MATRIGEL.TM. growth pattern; g) tumorigenic in congenitally athymic mice; h) no alkaline phosphatase activity; i) an ability to produce one or more of the following growth factors: 1) an osteoblastic differentiation growth factor, 2) a non-heparin binding mitogenic growth factor, 3) a first heparin binding mitogenic growth factor, 4) a second heparin binding mitogenic growth factor, and 5) a third heparin binding mitogenic growth factor; and an ability to be serially propagated greater than sixty population doublings.The present invention also relates to growth factors having the characteristics of growth factors isolated from the rat osteosarcoma cell line.Type: GrantFiled: June 24, 1992Date of Patent: February 15, 1994Assignee: The Procter & Gamble CompanyInventors: Claus-Jens W. Doersen, Robert J. Isfort
-
Patent number: 5286645Abstract: The present invention relates to a novel cell line isolated from a rat osteosarcoma having the following characteristics: A) a non-expressed p53 protein; B) a normal RB-1 gene as compared to a non-tumorigenic Sprague-Dawley rat cell control; C) a normal c-fos gene as compared to a non-tumorigenic Sprague-Dawley rat cell control; D) a 50-fold amplified c-myc gene as compared to a non-tumorigenic Sprague-Dawley rat cell control; E) a monolayer MATRIGEL.TM. growth pattern; F) tumorigenic in nude mice; G) normal alkaline phosphatase activity; H) an ability to be serially propagated greater than fifty population doublings; I) an ability to produce a growth factor selected from the group consisting of: 1) a mesenchymal inhibitory growth factor; 2) a non-heparin binding mitogenic growth factor; 3) a first heparin binding mitogenic growth factor; 4) a second heparin binding mitogenic growth factor; 5) a third heparin binding mitogenic growth factor; and 6) a fourth heparin binding mitogenic growth factor.Type: GrantFiled: June 24, 1992Date of Patent: February 15, 1994Assignee: The Procter & Gamble CompanyInventors: Claus-Jens W. Doersen, Robert J. Isfort
-
Patent number: 5264358Abstract: The present invention relates to a novel cell line isolated from a rat osteosarcoma wherein the cell line has the following characteristics: a) a mutated p53 gene incapable of expressing p53 protein, b) a normal RB-1 gene, c) a 10-fold amplified c-myc gene, d) a normal c-fos gene, e) a deregulated immediate early gene response, f) a canalicular network MATRIGEL.TM. growth pattern, g) tumorigenic in congenitally athymic mice, h) no alkaline phosphatase activity, i) an ability to produce one or more growth factors selected from the group consisting of: 1) an osteoblastic differentiation growth factor, 2) a non-heparin binding mitogenic growth factor, 3) a first heparin binding mitogenic growth factor, 4) a second heparin binding mitogenic growth factor, and 5) a third heparin binding mitogenic growth factor, and j) an ability to be serially propagated greater than sixty population doublings.Type: GrantFiled: June 24, 1992Date of Patent: November 23, 1993Assignee: The Procter & Gamble CompanyInventors: Claus-Jens W. Doersen, Robert J. Isfort